UK Pharma Gains Boost as Piramal Pharma Secures Key Manufacturing Certification

NEW YORK, NY – November 19, 2025

Piramal Pharma Solutions (PPS) has received updated Manufacturing Authorization (MHRA GMP) certificates for its Grangemouth, UK facility, covering all activities within its Helix building, including drug substance manufacture, warehousing, and laboratories. This renewal, announced earlier this week, underscores the company’s commitment to quality and regulatory compliance, and provides a critical boost to the UK’s burgeoning biopharmaceutical manufacturing sector. The certification is especially significant given the accelerating demand for complex therapies like antibody-drug conjugates (ADCs).

Strengthening UK’s Biomanufacturing Ecosystem

The Grangemouth facility is a cornerstone of PPS’s global network, specializing in the development and manufacturing of complex APIs, including those used in ADCs. The updated MHRA GMP certification isn’t merely a routine renewal; it reflects ongoing investment in cutting-edge technologies and a dedication to maintaining the highest standards of quality. “This certification is a testament to the hard work and dedication of our team in Grangemouth,” shared a source familiar with the facility’s operations. “It allows us to confidently serve our clients and deliver potentially life-saving therapies.”

The move is particularly welcome as the UK pharmaceutical industry seeks to solidify its position in a competitive global landscape. Recent years have seen increased calls for greater domestic manufacturing capacity, and PPS’s continued investment in the Grangemouth facility directly addresses this need. “It’s encouraging to see companies like Piramal Pharma Solutions doubling down on their commitment to the UK,” said an industry analyst specializing in pharmaceutical manufacturing. “This not only creates high-skilled jobs but also strengthens the UK’s resilience in the face of global supply chain disruptions.”

ADC Market Growth and Piramal’s Response

The demand for ADCs is fueled by the increasing prevalence of cancer and the promise of targeted therapies with reduced side effects. The global ADC market is projected to reach over $30 billion by 2034, representing a compound annual growth rate of over 10%. This rapid growth requires a significant expansion in manufacturing capacity, and PPS is strategically positioned to meet this demand.

The company’s ADCelerate™ program is designed to streamline the development of ADC therapies, offering clients accelerated timelines and fixed pricing. The program provides end-to-end services, from antibody production and conjugation to clinical and commercial manufacturing. “The ADCelerate™ program is a game-changer for companies developing ADC therapies,” commented a source within a pharmaceutical company utilizing the service. “It significantly reduces the time and cost associated with bringing these complex therapies to market.”

Ensuring Quality in Complex Manufacturing

The manufacturing of ADCs is inherently complex, requiring specialized expertise in areas such as antibody production, linker chemistry, and cytotoxic payload handling. Maintaining rigorous quality control throughout the manufacturing process is paramount to ensuring the safety and efficacy of these therapies. PPS’s Grangemouth facility has a longstanding track record of successful inspections by regulatory agencies, including the MHRA, FDA, and PMDA.

“We have a very robust quality system in place,” explained a quality assurance professional at the Grangemouth facility. “We invest heavily in training our personnel and ensuring that we adhere to the highest standards of GMP compliance.” The company’s commitment to quality extends beyond regulatory compliance; PPS also prioritizes continuous improvement and the implementation of innovative manufacturing technologies.

The Grangemouth facility’s capabilities also encompass the manufacture of highly potent APIs (HPAPIs), requiring stringent containment measures to protect both workers and the environment. The facility is equipped with state-of-the-art containment equipment and adheres to strict safety protocols. This demonstrates the company’s commitment to responsible manufacturing and environmental stewardship.

As the biopharmaceutical industry continues to evolve, companies like Piramal Pharma Solutions will play a critical role in bringing innovative therapies to patients. The company’s continued investment in the Grangemouth facility signals a long-term commitment to the UK pharmaceutical sector and a dedication to meeting the growing demand for complex therapies.